Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.


Journal

Cancer immunology, immunotherapy : CII
ISSN: 1432-0851
Titre abrégé: Cancer Immunol Immunother
Pays: Germany
ID NLM: 8605732

Informations de publication

Date de publication:
Oct 2020
Historique:
received: 31 12 2019
accepted: 12 05 2020
pubmed: 26 5 2020
medline: 7 10 2020
entrez: 26 5 2020
Statut: ppublish

Résumé

Pancreatic ductal adenocarcinoma is characterized by a strong immunosuppressive network with a dense infiltration of myeloid cells including myeloid-derived suppressor cells (MDSC). Two distinct populations of MDSC have been defined: polymorphonuclear MDSC (PMN-MDSC) and monocytic MDSC (M-MDSC). Several factors influence the development and function of MDSC including the transcription factor interferon regulatory factor 4 (IRF4). Here, we show that IRF4 deficiency accelerates tumor growth and reduces survival, accompanied with a dense tumor infiltration with PMN-MDSC and reduced numbers of CD8

Identifiants

pubmed: 32448983
doi: 10.1007/s00262-020-02605-9
pii: 10.1007/s00262-020-02605-9
pmc: PMC7511276
doi:

Substances chimiques

Biomarkers, Tumor 0
Interferon Regulatory Factors 0
interferon regulatory factor-4 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2101-2112

Subventions

Organisme : Deutsche Forschungsgemeinschaft
ID : 315563603
Organisme : Deutsche Forschungsgemeinschaft
ID : 329628492
Organisme : Deutsche Forschungsgemeinschaft
ID : 238187445
Organisme : Deutsche Forschungsgemeinschaft
ID : 385829722
Organisme : Deutsche Forschungsgemeinschaft
ID : 405344257
Organisme : H2020 Marie Skłodowska-Curie Actions
ID : 641549
Organisme : Narodowym Centrum Nauki (PL)
ID : 2016/23/B/NZ6/00086

Références

Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Cell. 1996 Oct 18;87(2):307-17
pubmed: 8861914
Cancer Immunol Immunother. 2011 Oct;60(10):1419-30
pubmed: 21644036
Nat Methods. 2015 May;12(5):445-52
pubmed: 25775045
Cancer Res. 2013 Mar 15;73(6):1709-20
pubmed: 23338611
HPB (Oxford). 2018 May;20(5):379-384
pubmed: 29336893
Nat Immunol. 2010 Oct;11(10):936-44
pubmed: 20729857
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
J Leukoc Biol. 2015 Dec;98(6):913-22
pubmed: 26337512
PLoS One. 2011;6(10):e25812
pubmed: 22003407
Sci Immunol. 2019 Oct 18;4(40):
pubmed: 31628161
Trends Cancer. 2018 Jun;4(6):418-428
pubmed: 29860986
Biotechniques. 2000 Jul;29(1):52, 54
pubmed: 10907076
J Leukoc Biol. 2016 Dec;100(6):1273-1284
pubmed: 27601624
Immunity. 2010 Jun 25;32(6):790-802
pubmed: 20605485
Blood. 2015 Feb 26;125(9):1452-9
pubmed: 25597637
J Clin Invest. 2013 Apr;123(4):1580-9
pubmed: 23454751
J Immunol Methods. 2014 Jun;408:89-100
pubmed: 24857755
Immunity. 2018 Jul 17;49(1):178-193.e7
pubmed: 29958801
J Immunother Cancer. 2019 Nov 6;7(1):288
pubmed: 31694706
Cell Rep. 2016 Jun 14;15(11):2462-74
pubmed: 27264183
Immunity. 2016 Sep 20;45(3):626-640
pubmed: 27637148
Cancer Gene Ther. 2016 Jun;23(6):188-98
pubmed: 27199222
Int J Cancer. 2007 Aug 15;121(4):699-705
pubmed: 17534898
Immunobiology. 2010 Sep-Oct;215(9-10):821-5
pubmed: 20580461
J Clin Invest. 2013 Oct;123(10):4464-78
pubmed: 24091328
J Immunol. 2014 Jun 15;192(12):5881-93
pubmed: 24835398
Immunity. 2006 Aug;25(2):225-36
pubmed: 16919487
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
J Cancer Ther. 2013 May;4(3):797-803
pubmed: 24089656
Cancer Res. 2007 Oct 1;67(19):9518-27
pubmed: 17909062
Immunity. 2016 Sep 20;45(3):669-684
pubmed: 27637149
Immunity. 2013 Nov 14;39(5):833-45
pubmed: 24211184
Nat Immunol. 2006 Jul;7(7):773-82
pubmed: 16767092
Eur J Immunol. 2014 Jul;44(7):1886-95
pubmed: 24782159
Nat Rev Immunol. 2012 Mar 22;12(4):253-68
pubmed: 22437938

Auteurs

Philipp Metzger (P)

Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Sabrina V Kirchleitner (SV)

Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
Department of Neurosurgery, University Hospital, LMU Munich, Munich, Germany.

Daniel F R Boehmer (DFR)

Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.

Christine Hörth (C)

Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.

Angelika Eisele (A)

Institute for Medical Information Processing, Biometry, and Epidemiology - IBE, Chair of Public Health and Health Services Research, LMU Munich, Munich, Germany.
Pettenkofer School of Public Health, Munich, Germany.

Steffen Ormanns (S)

Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.

Matthias Gunzer (M)

Institute for Experimental Immunology and Imaging, University Hospital, University Duisburg- Essen, Essen, Germany.
Leibniz Institute for Analytical Sciences - ISAS, Dortmund, Germany.

Maciej Lech (M)

Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany.

Kirsten Lauber (K)

Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany.

Stefan Endres (S)

Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
German Center for Translational Cancer Research (DKTK), Partner Site, Munich, Germany.
Einheit für Klinische Pharmakologie (EKLiP), Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Neuherberg, Germany.

Peter Duewell (P)

Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.
Institute of Innate Immunity, University of Bonn, Bonn, Germany.

Max Schnurr (M)

Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany. max.schnurr@med.uni-muenchen.de.

Lars M König (LM)

Center of Integrated Protein Science Munich (CIPSM) and Division of Clinical Pharmacology, University Hospital, LMU Munich, Munich, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH